AI in Trial Eligibility Screening Market Size, Share & Industry Analysis, By Component (Software/Platforms and Services), By Deployment (Cloud-Based, On-Premise, and Hybrid), By Technology (NLP, Machine Learning & Deep Learning, and Generative AI/LLMs), By Phase (Phase I, Phase II, Phase III, and Phase IV), By Function (Protocol Criteria Extraction, Patient-Trial Matching, and EHR/EMR Screening Automation), By Therapeutic Area (Oncology, Rare Diseases, and Neurology), By End User (Pharmaceutical & Biotech Companies, CROs, and Hospitals & Trial Sites), and Regional Forecast, 2026-2034